Loading
After platinum chemotherapy, the combination of the kinase inhibitor lenvatinib and pembrolizumab lengthened survival compared with doxorubicin or paclitaxel in advanced endometrial cancer, including in the mismatch repair-proficient majority.
Phase 3 trial of 827 patients with advanced endometrial cancer after one prior platinum regimen randomised to lenvatinib plus pembrolizumab or physician's choice of doxorubicin or weekly paclitaxel.
In mismatch repair-proficient disease median overall survival was 17.4 versus 12.0 months (hazard ratio 0.68) and median progression-free survival 6.6 versus 3.8 months; results were similar in the whole population. Grade 3 or higher adverse events occurred in 89 percent of the combination arm.
Lenvatinib-pembrolizumab is the standard second-line treatment for mismatch repair-proficient endometrial cancer after platinum, though its toxicity is considerable and its place after first-line immunotherapy is unclear.
Shares KEYNOTE-775 / Study 309, Lenvatinib, Pembrolizumab.
Shares Advanced or recurrent endometrial cancer, New England Journal of Medicine, Pembrolizumab.
Shares Lenvatinib, Pembrolizumab.
Shares Lenvatinib, Pembrolizumab.
Shares Lenvatinib, Pembrolizumab.
Shares Advanced or recurrent endometrial cancer, Lenvatinib.
Shares Lenvatinib, Pembrolizumab.
Shares Lenvatinib, Pembrolizumab.